[Reply to Letter to the Editor in reference to " Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]. FE. 2017;18(1). doi:10.7175/fe.v18i1.1329